Deep Brain Stimulation News and Research

RSS

Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. The procedure is also used to treat essential tremor, a common neurological movement disorder. At present, the procedure is used only for patients whose symptoms cannot be adequately controlled with medications.

NewYork-Presbyterian/WCMC first in N.Y. City to offer INTRABEAM radiotherapy

NewYork-Presbyterian Hospital/Weill Cornell Medical Center is the first and only hospital in the five boroughs of New York City to offer women with early stage breast cancer INTRABEAM radiotherapy, an innovative radiation treatment delivered in a single dose at the time of surgery.

6 Jul 2012

Single dose breast cancer treatment helps forego 6-7 week radiation regimen

5 Jul 2012

Small coils activate neurons to modulate brain-cell activity

Magnetic fields generated by microscopic devices implanted into the brain may be able to modulate brain-cell activity and reduce symptoms of several neurological disorders.

27 Jun 2012

Deep brain stimulation reduces binge eating

Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

DBS can improve muscle symptoms in patients with Parkinson's

Patients with Parkinson's disease who undergo deep brain stimulation (DBS)—a treatment in which a pacemaker-like device sends pulses to electrodes implanted in the brain—can expect stable improvement in muscle symptoms for at least three years, according to a Department of Veterans Affairs study appearing in the most recent issue of the journal Neurology.

22 Jun 2012

Deep brain stimulation remains an effective treatment for Parkinson's

A "brain pacemaker" called deep brain stimulation (DBS) remains an effective treatment for Parkinson's disease for at least three years, according to a study in the June 2010 online issue of Neurology, the medical journal of the American Academy of Neurology.

21 Jun 2012

NewYork-Presbyterian/WCMC join new MDS Clinical Research Consortium

NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium.

20 Jun 2012

Researchers unlock structure of STING protein

Researchers at Weill Cornell Medical College have unlocked the structure of a key protein that, when sensing certain viruses and bacteria, triggers the body's immediate immune response.

20 Jun 2012

High doses of tiny milk vitamin produces numerous health benefits in mice

A novel form of vitamin B3 found in milk in small quantities produces remarkable health benefits in mice when high doses are administered, according to a new study conducted by researchers at Weill Cornell Medical College and the Polytechnic School in Lausanne, Switzerland.

15 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Mazor Robotics successfully completes first robot-guided brain surgical procedures

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced the successful completion of the first robot-guided brain surgical procedures, which were performed with Mazor Robotics' technology.

11 Jun 2012

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Great Lakes NeuroTechnologies announced today that the U.S. Patent Office has issued claims under patent number 8,187,209 covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

6 Jun 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Researchers identify novel base modification in RNA

Over the past decade, research in the field of epigenetics has revealed that chemically modified bases are abundant components of the human genome and has forced us to abandon the notion we've had since high school genetics that DNA consists of only four bases.

18 May 2012